Abstract

Three experiments were conducted to evaluate elevated dietary NaCl levels as a means of offsetting industry-observed reductions of growth, feed intake, and feed efficiency associated with early (35-d) coccidiostat withdrawal. In the first experiment, monensin (100 ppm) was withdrawn and dietary salt levels of 0.33, 0.48, 0.63, 0.78, or 0.93% provided from 35 to 42 d of age. Experiments 2 and 3 involved lasalocid (110 ppm) withdrawal and slat amounts of 0.33, 0.53, 0.73, or 0.93%. In all studies, a positive control of 0.33% salt and the coccidiostat was also given. Monensin withdrawal reduced body weight gain, which was not overcome by slat addition. Feed efficiency during the 1-wk period was improved to the level of the group receiving continued medication by salt amounts of 0.78% or above. In contrast to industry field observations, removal of lasalocid did not reduce body weight gain, feed intake, or water consumption, and elevation of salt levels resulted in no consistent improvements of weight gain, feed intake, or feed conversion. Water intake increased proportionally as salt concentration increased. Elevated salt levels do not appear to be a reliable means of offsetting reduced performance related to early coccidiostat withdrawal, nor were such performance problems demonstrable for lasalocid in these trials.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call